Drug
Lorlatinib clinical trials
Also written PF-06463922 and Lorbrena.
Keep track of what changes. Save the lorlatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2020 (7)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 7 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 26
Pfizer (17) · Guangdong Association of Clinical Trials (4) · Intergroupe Francophone de Cancerologie Thoracique (2) · Memorial Sloan Kettering Cancer Center (1) · CStone Pharmaceuticals (1) · Guangdong Provincial People's Hospital (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · University of Milano Bicocca (1)
Often tested with
Tested in the same studies.
Carboplatin (3) · Crizotinib (3) · Olaparib (2) · Dabrafenib (2) · Trametinib (2) · Erlotinib (2) · Pertuzumab (2) · Vemurafenib (2)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses lorlatinib is read from its arms, and is right about nine times in ten.
Testing it · 46
- Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World ContextRecruitingNot applicablePfizerNCT06487078Written as Lorlatinib
- Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT07415005Written as Lorlatinib
- AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerRecruitingPhase 1Chugai PharmaceuticalNCT07617337Written as Lorlatinib
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingPhase 3Children's Oncology GroupNCT03126916Written as Lorlatinib
- Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCNot yet recruitingPhase 2Guangdong Association of Clinical TrialsNCT07750704Written as Lorlatinib
- Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionRecruitingEarly Phase 1Nationwide Children's HospitalNCT06333899Written as Lorlatinib
- Lorlatinib in ROS1+ NSCLC With Brain MetastasisNot yet recruitingPhase 2Hunan Cancer HospitalNCT07083687Written as Lorlatinib 100 mg
- Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial TranscriptomicsNot yet recruitingPhase 4The First Affiliated Hospital of Guangzhou Medical UniversityNCT06893354Written as lorlatinib
- Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung AdenocarcinomaNot yet recruitingPhase 3Guangdong Association of Clinical TrialsNCT06858410Written as lorlatinib
- Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung CancerNot yet recruitingPhase 2Peking University People's HospitalNCT06682884Written as Lorlatinib 100 mg
- A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on LorlatinibRecruitingPhase 2Centro di Riferimento Oncologico - AvianoNCT06378892Written as Lorlatinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Lorlatinib
- Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLCRecruitingPhase 2Guangdong Association of Clinical TrialsNCT06092086Written as Loratinib
- Lorlatinib Continuation StudyActive, not recruitingPhase 4PfizerNCT05144997Written as Lorlatinib
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung CancerActive, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06007937Written as Lorlatinib
- A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive LymphomaCompletedPhase 2University of Milano BicoccaNCT03505554Written as Lorlatinib
- A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung CancerActive, not recruitingPhase 2CStone PharmaceuticalsNCT05297890Written as Lorlatinib
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedPhase 2National Cancer Institute (NCI)NCT03737994Written as Lorlatinib
- Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal MetastasesActive, not recruitingPhase 4Guangdong Association of Clinical TrialsNCT06282874Written as Lorlatinib
- Induction Lorlatinib in Stage III Non-small Cell Lung CancerActive, not recruitingPhase 2Guangdong Provincial People's HospitalNCT05740943Written as Lorlatinib
See all 46 studies that test lorlatinib →
Given in every arm · 3 — lorlatinib is usual care beside what is tested
- Study of NXP900 With Lorlatinib in ALK+ Lung CancerRecruitingPhase 1Nuvectis Pharma, Inc.NCT07784959Written as Lorlatinib
- PF-07284892 in Participants With Advanced Solid TumorsTerminatedPhase 1PfizerNCT04800822Written as lorlatinib
- Lorlatinib Combinations in Lung CancerStatus unknownPhase 1/2Massachusetts General HospitalNCT04292119Written as Lorlatinib
Codes
What other systems call lorlatinib · ClinicalTrials.gg INT000046
- MeSH (NLM) C000590786lorlatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) OSP71S83EULORLATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2103164Confirmed FDA, Wikidata
- Wikidata Q27285820lorlatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C113655LorlatinibOne source FDA
- DrugBank DB12130One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000590786 | lorlatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | OSP71S83EU | LORLATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2103164 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27285820 | lorlatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113655 | Lorlatinib | One source FDA |
| DrugBank | DB12130 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.